Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I

Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlova, Kristina V., Yanus, Grigory A., Aleksakhina, Svetlana N., Venina, Aigul R., Iyevleva, Aglaya G., Demidov, Lev V., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477486/
https://www.ncbi.nlm.nih.gov/pubmed/31043947
http://dx.doi.org/10.1159/000495782
_version_ 1783413026669461504
author Orlova, Kristina V.
Yanus, Grigory A.
Aleksakhina, Svetlana N.
Venina, Aigul R.
Iyevleva, Aglaya G.
Demidov, Lev V.
Imyanitov, Evgeny N.
author_facet Orlova, Kristina V.
Yanus, Grigory A.
Aleksakhina, Svetlana N.
Venina, Aigul R.
Iyevleva, Aglaya G.
Demidov, Lev V.
Imyanitov, Evgeny N.
author_sort Orlova, Kristina V.
collection PubMed
description Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patient with KIT р.T632I mutation, who failed to respond to imatinib.
format Online
Article
Text
id pubmed-6477486
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-64774862019-05-01 Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I Orlova, Kristina V. Yanus, Grigory A. Aleksakhina, Svetlana N. Venina, Aigul R. Iyevleva, Aglaya G. Demidov, Lev V. Imyanitov, Evgeny N. Case Rep Oncol Case Report Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patient with KIT р.T632I mutation, who failed to respond to imatinib. S. Karger AG 2019-01-23 /pmc/articles/PMC6477486/ /pubmed/31043947 http://dx.doi.org/10.1159/000495782 Text en Copyright © 2019 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Orlova, Kristina V.
Yanus, Grigory A.
Aleksakhina, Svetlana N.
Venina, Aigul R.
Iyevleva, Aglaya G.
Demidov, Lev V.
Imyanitov, Evgeny N.
Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
title Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
title_full Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
title_fullStr Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
title_full_unstemmed Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
title_short Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
title_sort lack of response to imatinib in melanoma carrying rare kit mutation p.t632i
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477486/
https://www.ncbi.nlm.nih.gov/pubmed/31043947
http://dx.doi.org/10.1159/000495782
work_keys_str_mv AT orlovakristinav lackofresponsetoimatinibinmelanomacarryingrarekitmutationpt632i
AT yanusgrigorya lackofresponsetoimatinibinmelanomacarryingrarekitmutationpt632i
AT aleksakhinasvetlanan lackofresponsetoimatinibinmelanomacarryingrarekitmutationpt632i
AT veninaaigulr lackofresponsetoimatinibinmelanomacarryingrarekitmutationpt632i
AT iyevlevaaglayag lackofresponsetoimatinibinmelanomacarryingrarekitmutationpt632i
AT demidovlevv lackofresponsetoimatinibinmelanomacarryingrarekitmutationpt632i
AT imyanitovevgenyn lackofresponsetoimatinibinmelanomacarryingrarekitmutationpt632i

Ejemplares similares